Ha Tay Pharmaceutical JSC (HNX:DHT)
Vietnam · Delayed Price · Currency is VND 49,900
+1,000 (2.04%)
At close: Nov 3, 2026
Ha Tay Pharmaceutical JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,381,679 | 2,402,040 | 2,086,353 | 1,999,304 | 1,837,395 | 1,609,364 | |
Revenue Growth | 5.78% | 15.13% | 4.35% | 8.81% | 14.17% | -19.79% |
Cost of Revenue | 2,193,672 | 2,192,851 | 1,866,534 | 1,795,972 | 1,650,138 | 1,455,342 |
Gross Profit | 188,007 | 209,189 | 219,818 | 203,331 | 187,256 | 154,022 |
Selling, General & Admin | 176,008 | 168,478 | 143,306 | 104,115 | 84,806 | 91,953 |
Operating Expenses | 176,008 | 168,478 | 143,306 | 104,115 | 84,806 | 91,953 |
Operating Income | 11,998 | 40,711 | 76,513 | 99,216 | 102,450 | 62,070 |
Interest Expense | -12,064 | -13,056 | -13,449 | -20,099 | -14,304 | -13,993 |
Interest & Investment Income | - | 7,240 | 7,572 | 19,614 | 22,044 | 29,451 |
Earnings From Equity Investments | 2,270 | 7,389 | 6,756 | 4,171 | 2,971 | 1,996 |
Currency Exchange Gain (Loss) | 2,928 | -2,999 | -3,806 | - | -948.89 | -9.65 |
Other Non Operating Income (Expenses) | 43,780 | 29,186 | 21,485 | 7,442 | 10,925 | 10,076 |
EBT Excluding Unusual Items | 48,913 | 68,471 | 95,072 | 110,344 | 123,137 | 89,590 |
Gain (Loss) on Sale of Investments | - | 4,712 | - | - | - | - |
Gain (Loss) on Sale of Assets | 12.7 | 126.34 | 150 | - | 86.82 | -77.14 |
Pretax Income | 48,925 | 73,309 | 95,222 | 110,344 | 123,224 | 89,513 |
Income Tax Expense | 12,485 | 14,269 | 20,028 | 21,382 | 24,259 | 18,123 |
Earnings From Continuing Operations | 36,440 | 59,040 | 75,194 | 88,961 | 98,964 | 71,390 |
Minority Interest in Earnings | -2,466 | -5,384 | -3,422 | -3,906 | -3,753 | -3,444 |
Net Income | 33,974 | 53,657 | 71,772 | 85,056 | 95,211 | 67,946 |
Net Income to Common | 33,974 | 53,657 | 71,772 | 85,056 | 95,211 | 67,946 |
Net Income Growth | -48.96% | -25.24% | -15.62% | -10.67% | 40.13% | -26.18% |
Shares Outstanding (Basic) | - | 91 | 100 | 61 | 89 | 89 |
Shares Outstanding (Diluted) | - | 91 | 100 | 61 | 89 | 89 |
Shares Change | - | -8.17% | 62.83% | -31.61% | 0.77% | -0.77% |
EPS (Basic) | - | 586.46 | 720.37 | 1390.07 | 1064.19 | 765.31 |
EPS (Diluted) | - | 586.46 | 720.37 | 1390.07 | 1064.19 | 765.31 |
EPS Growth | - | -18.59% | -48.18% | 30.62% | 39.05% | -25.61% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 128,714 | 176,961 | -115,173 | -95,725 | -286,024 | -83,817 |
Free Cash Flow Per Share | - | 1934.16 | -1155.99 | -1564.44 | -3196.95 | -944.08 |
Dividend Per Share | - | - | - | - | 295.159 | 295.159 |
Dividend Growth | - | - | - | - | 0% | - |
Gross Margin | 7.89% | 8.71% | 10.54% | 10.17% | 10.19% | 9.57% |
Operating Margin | 0.50% | 1.70% | 3.67% | 4.96% | 5.58% | 3.86% |
Profit Margin | 1.43% | 2.23% | 3.44% | 4.25% | 5.18% | 4.22% |
Free Cash Flow Margin | 5.40% | 7.37% | -5.52% | -4.79% | -15.57% | -5.21% |
EBITDA | 49,701 | 64,854 | 96,993 | 116,294 | 119,898 | 78,721 |
EBITDA Margin | 2.09% | 2.70% | 4.65% | 5.82% | 6.53% | 4.89% |
D&A For EBITDA | 37,702 | 24,143 | 20,481 | 17,078 | 17,448 | 16,651 |
EBIT | 11,998 | 40,711 | 76,513 | 99,216 | 102,450 | 62,070 |
EBIT Margin | 0.50% | 1.70% | 3.67% | 4.96% | 5.58% | 3.86% |
Effective Tax Rate | 25.52% | 19.46% | 21.03% | 19.38% | 19.69% | 20.25% |
Revenue as Reported | 2,381,679 | 2,402,040 | 2,086,353 | 1,999,304 | 1,837,395 | 1,609,364 |